{"schema_version":"secwatch.filing_event.v1","accession":"0001232524-24-000014","form_type":"8-K","ticker":"JAZZ","cik":"0001232524","company_name":"Jazz Pharmaceuticals plc","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.614415+00:00","generated_at":"2026-06-05T08:18:05.433129+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Jazz Pharma FY23 net income $414.8M vs loss; guides FY24 rev $4.0-4.2B","bullets":["Total revenue $3.84B in 2023, up 5% YoY; Q4 revenue $1.01B, up 4% YoY.","GAAP EPS $6.10; non-GAAP adjusted EPS $18.29, vs. $13.20 in 2022.","Key growth drivers: Xywav +33%, Epidiolex +15%, Rylaze +40% in 2023.","2024 guidance: revenue $4.0-4.2B, non-GAAP adjusted EPS $18.15-19.35.","Oncology revenue surpassed $1B in 2023; $161M remains for share buybacks."],"urls":{"canonical":"https://secwatch.observer/filing/0001232524-24-000014","json":"https://secwatch.observer/filing/0001232524-24-000014.json","markdown":"https://secwatch.observer/filing/0001232524-24-000014.md","text":"https://secwatch.observer/filing/0001232524-24-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1232524/000123252424000014/0001232524-24-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1232524/000123252424000014/jazz-20240228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:18:05.433129+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}